Richard Pazdur

Richard Pazdur

Auto-generated profile, based on publicly available information

Richard Pazdur

Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
ESEmma C. Scott
Emma C. Scott
ABAndrea C. Baines
Andrea C. Baines
YGYutao Gong
Yutao Gong
RMRodney Moore
Rodney Moore
GPGulsum E. Pamuk
Gulsum E. Pamuk
JBJulia A. Beaver
Julia A. Beaver

5 December 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JFJaleh Fallah
Jaleh Fallah
SASundeep Agrawal
Sundeep Agrawal
HGHaley Gittleman
Haley Gittleman
MFMallorie H. Fiero
Mallorie H. Fiero
SSSriram Subramaniam
Sriram Subramaniam
PKPaul G. Kluetz
Paul G. Kluetz
On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. The recommended 177Lu-PSMA-617 dose is 7.4 gigabecquerels (GBq; 200 mCi) intravenously every 6 weeks for up to six doses, or until disease progression or unacceptable toxicity. The FDA granted traditional approval based on VISION (NCT03511664), which was a randomized (2:1), multicenter, open-label trial that assessed the efficacy and safety of 177Lu-PSMA-617 plus best standard of care (BSoC; n = 551) or BSoC alone (n = 280) in men with progressive, PSMA-positive mCRPC. Patients were required to have received ≥1 androgen receptor pathway inhibitor, and one or two prior taxane-based chemotherapy regimens. There was a statistically significant and clinically meaningful improvement in overall survival (OS), with a median OS of 15.3 months in the 177Lu-PSMA-617 plus BSoC arm and 11.3 months in the BSoC arm, respectively (HR: 0.62; 95% confidence interval: 0.52–0.74; P < 0.001). The most common adverse reactions (≥20%) occurring at a higher incidence in patients receiving 177Lu-PSMA-617 were fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. The most common laboratory abnormalities that worsened from baseline in ≥30% of patients receiving 177Lu-PSMA-617 were decreased lymphocytes, decreased hemoglobin, decreased leukocytes, decreased platelets, decreased calcium, and decreased sodium. This article summarizes the FDA review of data supporting traditional approval of 177Lu-PSMA-617 for this indication.

20 October 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JZJeanne Fourie Zirkelbach
Jeanne Fourie Zirkelbach
MSMirat Shah
Mirat Shah
JVJonathon Vallejo
Jonathon Vallejo
JCJoyce Cheng
Joyce Cheng
AAAmal Ayyoub
Amal Ayyoub
MTMarc R. Theoret
Marc R. Theoret
This review highlights strategies to integrate dose optimization into premarketing drug development and discusses the underlying statistical principles. Poor dose optimization can have negative consequences for patients, most commonly because of toxicity, including poor quality of life, reduced effectiveness because of inability of patients to stay on current therapy or receive subsequent therapy because of toxicities, and difficulty in developing combination regimens. We reviewed US Food and Drug Administration initial approvals (2019-2021) of small molecules and antibody-drug conjugates for oncologic indications to determine the proportion with a recommended dosage at the maximum tolerated dose or the maximal administered dose, to characterize the use of randomized evaluations of multiple dosages in dose selection, to describe the frequency of dose modifications at the recommended dosage, and to identify case examples that highlight key principles for premarket dose optimization during drug development. Herein, we highlight major principles for dose optimization and review examples of recent US Food and Drug Administration approvals that illustrate how investigation of dose- and exposure-response relationships and use of randomized dose trials can support dose optimization. Although there has been some progress, dose optimization through randomized dose evaluation in oncology trials is not routinely conducted. Dose optimization is essential to ensure that patients receive therapies which maximize efficacy while minimizing toxicity.

20 May 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MMMargret Merino
Margret Merino
YKYvette Kasamon
Yvette Kasamon
MTMarc Theoret
Marc Theoret
RPRichard Pazdur
Richard Pazdur
PKPaul Kluetz
Paul Kluetz
NGNicole Gormley
Nicole Gormley

22 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ADAsma Dilawari
Asma Dilawari
MSMirat Shah
Mirat Shah
GIGwynn Ison
Gwynn Ison
HGHaley Gittleman
Haley Gittleman
MFMallorie H. Fiero
Mallorie H. Fiero
LALaleh Amiri-Kordestani
Laleh Amiri-Kordestani
On November 14, 2022, the FDA granted accelerated approval to mirvetuximab soravtansine-gynx for treatment of adult patients with folate receptor-α (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic therapies. The VENTANA FOLR1 (FOLR-2.1) RxDx Assay was approved as a companion diagnostic device to select patients for this indication. Approval was based on Study 0417 (SORAYA, NCT04296890), a single-arm, multicenter trial. In 104 patients with measurable disease who received mirvetuximab soravtansine-gynx, the overall response rate was 31.7% [95% confidence interval (CI), 22.9–41.6] with a median duration of response of 6.9 months (95% CI, 5.6–9.7). Ocular toxicity was included as a Boxed Warning in the U.S. Prescribing Information (USPI) to alert providers of the risks of developing severe ocular toxicity including vision impairment and corneal disorders. Pneumonitis and peripheral neuropathy were additional important safety risks included as Warnings and Precautions in the USPI. This is the first approval of a targeted therapy for FRα-positive, platinum-resistant ovarian cancer and the first antibody–drug conjugate approved for ovarian cancer. This article summarizes the favorable benefit–risk assessment leading to FDA's approval of mirvetuximab soravtansine-gynx.

4 August 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MSMirat Shah
Mirat Shah
COChristy L. Osgood
Christy L. Osgood
AAAnup K. Amatya
Anup K. Amatya
MFMallorie H. Fiero
Mallorie H. Fiero
WPWilliam F. Pierce
William F. Pierce
LALaleh Amiri-Kordestani
Laleh Amiri-Kordestani
On July 26, 2021, the FDA granted approval to pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then continued as a single agent for adjuvant treatment following surgery for patients with high-risk, early-stage triple-negative breast cancer. Approval was based on results from KEYNOTE-522, an ongoing randomized (2:1) trial evaluating pembrolizumab or placebo in combination with chemotherapy for neoadjuvant treatment and then as a single agent for adjuvant treatment. The co-primary endpoints were pathological complete response (pCR) rate and event-free survival (EFS). The trial demonstrated an improvement in pCR and EFS in the pembrolizumab arm compared with the control arm. The number of patients who experienced an EFS event was 123 (16%) and 93 (24%), respectively [HR: 0.63, 95% confidence interval (CI), 0.48–0.82, P = 0.00031]. Patients on the pembrolizumab arm experienced EFS benefit regardless of tumor PD-L1 status. The absolute pCR rate improvement with the addition of pembrolizumab was 7.5% (95% CI, 1.6–13.4). Among patients receiving pembrolizumab, 44% experienced an immune-related adverse reaction. This article summarizes FDA's review of pembrolizumab and the data supporting the favorable benefit–risk assessment.